ArticleThe Korean journal of internal medicine2022
Clinical efficacy of adjuvant chemotherapy in stage IB (< 4 cm) non-small cell lung cancer patients with high-risk factors.
Article in The Korean journal of internal medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 29 citations in OpenAlex.
- Prognostic Impact of Visceral Pleural Invasion in Node-Negative Non-Small Cell Lung Cancer with Tumors ≤ 3 cm.Cancers · 2026Article
- Adjuvant targeted therapy in high-risk stage IB epidermal growth factor receptor-mutant lung cancer: Role of ground-glass opacity components.JTCVS open · 2026Article
- Vascular invasion-associated gene expression is detectable in pre-surgical biopsies of stage I lung adenocarcinoma.Nature communications · 2026Article
- TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non-small cell lung cancer.The Journal of thoracic and cardiovascular surgery · 2026Article
- Grade-driven adjuvant chemotherapy benefit in high-risk stage IB NSCLC: a retrospective cohort study.Journal of thoracic disease · 2025Article
- Adjuvant chemotherapy before osimertinib inTranslational lung cancer research · 2025Article
- Prognostic significance of micropapillary pattern and risk factors in patients with resected stage I lung adenocarcinoma and possible benefit of adjuvant therapy: a real-world multicenter study.Translational lung cancer research · 2025Article
- Middle lobe tumors and lymphovascular invasion as independent predictors of recurrence-free survival in stage I NSCLC.BMC pulmonary medicine · 2025Article
- Previous Suture Type and Diameter of Fistula Predict Overall Repair Success for Post-Pneumonectomy Bronchopleural Fistulas.Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2025Article
- Factors Associated with Postoperative Recurrence in Stage I to IIIA Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation: Analysis of Korean National Population Data.Cancer research and treatment · 2025Article
- [Advances in the Application of Adjuvant Chemotherapy and Targeted Therapy in Postoperative Patients with Stage I Lung Adenocarcinoma].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Review
- Lung carcinoma with adrenal metastasis and inferior vena cava thrombosis in an elderly patient with decompensated chronic liver disease: a case report.Annals of medicine and surgery (2012) · 2024Article
- Identification of a gene expression signature of vascular invasion and recurrence in stage I lung adenocarcinoma via bulk and spatial transcriptomics.bioRxiv : the preprint server for biology · 2024Article
- Impact of adjuvant chemotherapy on patients with stage IB non-small cell lung cancer with visceral pleural invasion.Journal of thoracic disease · 2024Article
- Exploring non-invasive precision treatment in non-small cell lung cancer patients through deep learning radiomics across imaging features and molecular phenotypes.Biomarker research · 2024Article
- A narrative review on perioperative systemic therapy in non-small cell lung cancer.Exploration of targeted anti-tumor therapy · 2024Review
- Adjuvant chemotherapy in pathological node-negative non-small cell lung cancer.Scientific reports · 2023Article
- Role of adjuvant treatment in stage IB non-small cell lung carcinoma.Translational lung cancer research · 2023Article
- Surgically Treated pT2aN0M0 (Stage IB) Non-Small Cell Lung Cancer: A 20-Year Single-Center Retrospective Study.Journal of clinical medicine · 2023Article
- Diagnosis, treatment, and prognosis of stage IB non-small cell lung cancer with visceral pleural invasion.Frontiers in oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsAdjuvant chemotherapy is the standard of care for resected stage II-IIIA non-small cell lung cancer (NCSLC). The efficacy of adjuvant chemotherapy in stage IB (< 4 cm) NSCLC with high-risk factors is controversial.
methodsThis retrospective multicenter study included 285 stage IB NSCLC patients with high-risk factors according to the 8th edition tumor, node, metastasis (TNM) classification from four academic hospitals. High-risk factors included visceral pleural invasion, vascular invasion, lymphatic invasion, lung neuroendocrine tumors, and micropapillary histology patterns.
resultsOf the 285 patients, 127 (44.6%) were included in the adjuvant chemotherapy group and 158 (55.4%) were included in the non-adjuvant chemotherapy group. The median follow-up was 41.5 months. Patients in the adjuvant chemotherapy group had a significantly reduced recurrence rate and risk of mortality than those in the non-adjuvant chemotherapy group (hazards ratio, 0.408; 95% confidence interval, 0.221 to 0.754; p = 0.004 and hazards ratio, 0.176; 95% confidence interval, 0.057 to 0.546; p = 0.003, respectively). Adjuvant chemotherapy should be particularly considered for the high-risk factors such as visceral pleural involvement or vascular invasion. Based on the subgroup analysis, adjuvant chemotherapy should be considered when visceral pleural involvement is present, even if the tumor size is < 3 cm.
conclusionAdjuvant chemotherapy may be useful for patients with stage IB NSCLC with high-risk factors and is more relevant for patients with visceral pleural involvement or vascular invasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.